When 38‑year‑old women are reassured by routine GP questioning that they are low risk because there is no family history, emerging research suggests that reassurance may be misplaced for a substantial proportion. A new study from researchers at Cambridge University and the Institute of Cancer Research warns that existing guidance could overlook many younger women who will develop breast cancer within a decade.
Key findings from the risk modelling
The research used the BOADICEA risk calculator — a tool that combines family history, lifestyle, reproductive factors and genetic data — to estimate who should be referred for further assessment. Applying the tool to all women under 50, the team concluded that roughly 26.5% would be classified as above average risk and referred on for more investigation.
By contrast, current NICE recommendations, which focus heavily on family history as a trigger for further assessment, would prompt referral in only 1.4% of women under 50.
| Approach | % of women under 50 referred | % of subsequent cancers caught (10 years) |
|---|---|---|
| BOADICEA applied to all | 26.5% | 34.8% |
| Current NICE criteria | 1.4% | 4.4% |
Why the gap exists
The researchers point out a critical reason for the wide disparity: about 73% of women under 50 who go on to develop breast cancer within ten years have no family history — the principal trigger the NICE guidance relies upon. That means a large share of those who later present with disease would not be identified by family‑history screening alone.
- Breast cancer is a leading cause of death among women under 50 in the UK.
- Approximately 1 in 7 women will develop breast cancer in their lifetime; only 5–10% of cases are linked to inherited genes.
- Most cases occur in older women: 96% are in those aged over 40, and 25% in those over 75.
Implications for primary care and policy
If the BOADICEA approach were adopted universally for under‑50s, many more women would be channelled into further assessment — and the model suggests that would capture a substantially larger share of those who will develop cancer within the following decade. That raises questions about GP workload, diagnostic capacity and the balance between wider assessment and potential over‑referral.
Guidance in England currently advises GPs to ask about family history when a woman is worried about her breast cancer risk, and sometimes when women are over 35 and using the combined oral contraceptive pill or considering hormone replacement therapy. The study underscores that hormones are only a modest risk factor compared with others such as alcohol intake and obesity, and that reliance on family history alone may miss the majority of younger cases.
What is known and what remains to be decided
The modelling does not change observed cancer rates, but it highlights how different assessment strategies identify different groups. Any move to broaden systematic risk assessment for younger women would require decisions about resources, prioritisation and how best to integrate genetic and lifestyle information into routine primary care without causing unnecessary alarm.
For clinicians and policymakers, the paper offers evidence that current NICE criteria may be insufficiently sensitive for younger women, and that tools like BOADICEA can substantially increase detection of those at elevated risk — at the cost of a much larger number being referred for further assessment.
